drugset / Trial / NCT02820311

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

NCT02820311

Phase 1 Completed 48 enrolled Mylan Inc. Theravance Biopharma · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate if TD-4208, an investigational drug being developed to treat people with chronic obstructive pulmonary disease (COPD), has any effect on the electrical activity of the heart.

Timeline

Start
2016-05
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Revefenacin Small molecule 175 ug Other
Subject Revefenacin Small molecule 700 ug Other

Indications

No indication recorded.